Pfizer is looking to newer products and acquisitions to offset a declining Covid business.
By Mariam Sunny and Christy Santhosh May 5 (Reuters) - Pfizer reported higher-than-expected sales and profit on Tuesday and ...
Pfizer’s $2.3 billion bet on Trillium Therapeutics doesn’t look like it will ever pay out, with the Big Pharma abandoning the ...
May 5 () - Pfizer on Tuesday reported first-quarter profit above Wall Street estimates, boosted by sustained demand for ...
Pfizer is also demonstrating that its commercial portfolio can flourish beyond the historically mammoth sales of its COVID-19 ...
Pfizer has been leaning on recently acquired products to offset a looming patent cliff.
Despite the continued decline of Pfizer's COVID-19 products, shares stayed stable on Tuesday morning after the New York ...
Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s ...
Pfizer Inc (NYSE:PFE, XETRA:PFE) reported first-quarter 2026 revenue and adjusted profit above Wall Street expectations on ...
Q1 2026 earnings call recap: revenue/EPS beat, 2026 guidance intact, Vyndamax & Comirnaty legal wins boost 2029+ outlook—read now.
Pfizer (PFE) stock gained 0.5% premarket after Q1 EPS of $0.75 topped forecasts. Eliquis drove revenue strength as company ...
Shares of Pfizer are down 50% from their 2021 high, and the yield is an alluring 6.4%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results